RPT-E-037 / Remedy Plan - LARVOL DELTA

Preclinical evaluation of a novel hyperbolic NAMPT inhibitor in combination with pan-RAS targeted therapies in pancreatic ductal adenocarcinoma (AACR 2026) - "Multiple KRAS-mutant PDAC cellular models, including KRASG12C inhibitor, KRASG12D inhibitor, and pan-RAS inhibitor (RMC6236)-resistant lines were treated with the hyperbolic NAMPT inhibitor RPT-E-037, RMC6236, or both. Dual inhibition of NAMPT-mediated NAD biosynthesis and KRAS signaling yields synergistic antitumor activity in PDAC, including models resistant to KRAS-targeted therapies. These findings support NAMPT-KRAS co-dependency as a therapeutically actionable vulnerability and justify further translational and in vivo studies to guide clinical development and biomarker-based patient selection."Generative AI was used for improving the language of the abstract"."

Combination therapy • Preclinical • Oncology • Pancreatic Ductal Adenocarcinoma • KRAS • NAMPT

Targeting NAMPT using Novel Inhibitor RPT-E-037 in Pancreatic Neuroendocrine Tumor (AACR 2026) - "RPT-E-037 synergized with pNETs standard of care mTOR targeted agent everolimus in both BON-1 and QGP-1 cell lines leading to superior cell deaths (CI<1). For the first time, this study reveals the therapeutic potential of RPT-E-037, a new NAMPT inhibitor, for pNETs in preclinical models. RPT-E-037 shows promise as a novel NAMPT inhibitor and deserves further clinical investigation for pNETs.Generative AI was used for improving the language of the abstract."

Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • NAMPT